Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion. by Ito Yuka et al.
Comparison of single injection and three
monthly injections of intravitreal bevacizumab
for macular edema associated with branch
retinal vein occlusion.
著者 Ito Yuka, SAISHIN Yoshitsugu, SAWADA Osamu,
KAKINOKI Masashi, Miyake Taichiro, Sawada
Tomoko, KAWAMURA Hajime, OHJI Masahito
journal or
publication title
Clinical ophthalmology
volume 9
page range 175-180
year 2015-12
URL http://hdl.handle.net/10422/00012476
doi: 10.2147/OPTH.S76261
Creative Commons : 表示 - 非営利
http://creativecommons.org/licenses/by-nc/3.0/deed.ja
© 2015 Ito et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Clinical Ophthalmology 2015:9 175–180
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
175
O r i g i n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OPTH.S76261
Comparison of single injection and three monthly 
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Purpose: Our aim was to compare the 1 year efficacy and safety results of intravitreal 
bevacizumab (IVB) in two prospective, consecutive groups of patients with macular edema 
(ME) following branch retinal vein occlusion (BRVO).
Patients and methods: Twenty-five eyes with ME after BRVO received one IVB injection 
(single-injection group) and 27 eyes received three monthly IVB injections (three-injection 
group). Both groups were followed monthly for 12 months. The best-corrected visual acuity 
(BCVA) and the central foveal thickness (CFT) on optical coherence tomography were evalu-
ated before and after treatment. Patients were eligible to receive an IVB injection if the mean 
CFT increased 100 µm or more or the BCVA decreased 0.1 logarithm of the minimum angle 
of resolution (logMAR) unit or more compared with values measured on the last visit.
Results: The mean logMAR BCVA and CFT, respectively, improved from 0.56 to 0.33 and 
from 598 µm to 348 µm in the single-injection group (P0.001) and from 0.55 to 0.26 and 
from 514 µm to 293 µm in the three-injection group (P0.001). During the study period, the 
mean total number of injections was significantly smaller in the single-injection group than in 
the three-injection group (2.1 and 4.3, respectively, P0.001). No serious complications related 
to the IVB injections developed in either group.
Conclusion: The single-injection group achieved similar visual outcomes for ME secondary 
to BRVO with fewer injections compared with the three-injection group.
Keywords: branch retinal vein occlusion, bevacizumab, single intravitreal injection, three 
monthly intravitreal injections 
Introduction
Retinal occlusive disorders are second in prevalence after diabetic retinopathy.1 Macular 
edema (ME) associated with branch retinal vein occlusion (BRVO) is a common com-
plication.2 Although a study reported that macular grid-pattern laser photocoagulation 
improved visual acuity (VA), most patients had limited improvement in VA in other 
studies.2–5 Some studies have reported that intravitreal injection of triamcinolone 
acetonide decreased ME, but this treatment frequently caused adverse effects.1,2,6,7
Intravitreal bevacizumab (IVB) injections have been reported to be effective.8–11 
However, IVB injection is an off-label treatment and there are no specific recommen-
dations regarding the frequency of injection for effective long-term results.
We studied two prospective, consecutive groups of patients with ME following 
BRVO. One group received a single IVB injection, the other received three monthly IVB 
injections, and the 1 year efficacy and safety results were compared in the two groups.
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Patients and methods
inclusion criteria
Patients with ME after BRVO were included. Patients had a 
central foveal thickness (CFT) exceeding 300 µm on optical 
coherence tomography (OCT; Cirrus HD-OCT, Carl Zeiss 
Meditec AG, Jena, Germany) and a decimal VA of 0.5 or 
worse.
exclusion criteria
Eyes with glaucoma, diabetic retinopathy, and inflamma-
tory disease were excluded. Patients with a recent history 
of stroke or myocardial infarction, unstable angina pectoris, 
uncontrolled hypertension, uncompensated renal insuf-
ficiency, pregnancy, prior anti-vascular endothelial growth 
factor (VEGF) treatment or allergy to bevacizumab were 
also excluded. 
re-injection criteria
Patients were eligible to receive an IVB injection if there 
was an increase in the mean CFT of 100 µm or more or a 
decrease in the BCVA of 0.1 logarithm of the minimum angle 
of resolution (logMAR) unit or more compared with values 
measured on the last visit.
single-injection group
We prospectively analyzed 25 consecutive eyes of 25 patients 
(nine males and 16 females) with ME following BRVO who 
were enrolled from August 2007 to March 2009 at the Shiga 
University of Medical Science Hospital. The Institutional 
Review Board of the hospital approved the study protocol. 
Patients received one IVB injection at baseline and no addi-
tional treatments were performed within 3 months of the 
initial injection (month 1 and month 2). IVB was adminis-
tered as needed if the pre-specified criteria were met during 
months 3 to 11 (referred to as the pro re nata [PRN] period). 
Four patients received prior treatment with photocoagulation 
(three patients) or posterior sub-tenon injection of triamci-
nolone acetonide (one patient) more than 9 months prior to 
the first IVB injection.
Three-injection group
We prospectively consecutively studied 27 eyes of 27 patients 
(15 males and 12 females) with ME after BRVO who were 
enrolled from December 2009 to November 2010 at the Shiga 
University of Medical Science Hospital. The Institutional 
Review Board of the Shiga University of Medical Science 
Hospital approved the study protocol. Patients received 
three monthly IVB injections (day 0 – month 2). IVB was 
then administered as needed if pre-specified criteria were met 
during the PRN period. Two patients received prior treatment 
with photocoagulation (one patient) or posterior sub-tenon 
injection of triamcinolone acetonide (one patient) more than 
5 months prior to the first IVB injection.
study visits and assessments
Patients were examined at baseline (day 0), week 1, and 
then monthly from months 1 to 12. At each visit, patients 
underwent a complete ocular examination. The BCVA was 
expressed as decimal VA using a Landolt C chart and con-
verted to logMAR VA for analysis. The CFT was measured 
using the macular cube 512×128 mode protocol and defined 
as the central area within a diameter of 1 mm on Cirrus HD-
OCT images.
statistical analysis
Data were analyzed using SPSS II for Windows (SPSS Inc., 
Chicago, IL, USA). Differences in the logMAR BCVA and 
CFT between baseline and 12 months after the first injection 
were analyzed using a paired samples t-test. Differences in 
the changes in the logMAR BCVA and CFT between the 
two treatment groups were analyzed using a two-sample 
Student’s t-test. A P-value less than 0.05 was considered to 
be statistically significant.
A chi-square test was used to compare the difference in 
percentage of patients who gained 0.3 logMAR units or more 
in BCVA between the two groups.
Results
Baseline characteristics
The baseline characteristics are shown in Table 1. The 
mean (± standard deviation) age was 69.3±7.8 years (range 
55–81) in the single-injection group and 68.0±10.7 years 
(range 44–88) in the three-injection group. There were no 
significant differences between the groups in gender, age, 
BCVA, or CFT.
Duration of BrVO before the treatment  
There was no significant difference in mean interval between 
the onset of BRVO and the first intravitreal injection of 
bevacizumab (3.57±2.87 months [range 1–11] in the single-
injection group versus (vs) 3.73±3.03 months [range 1–12] 
in the three-injection group; P=0.85).
Va
The mean logMAR BCVA values are shown in Figure 1. 
There was no significant difference in the mean logMAR 
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BCVA at baseline (0.56±0.22 [range 0.30–1.15] in the 
single-injection group vs 0.55±0.24 [range 0.30–1.05] in 
the three-injection group; P=0.84). In the single-injection 
group, the mean logMAR BCVA improved from 0.56±0.22 
(range 0.30–1.15) at baseline to 0.47±0.26 (range 0–1.05), 
0.42±0.33 (range 0–1.15), 0.39±0.27 (range 0.05–1.05), and 
0.33±0.29 (range, -0.18–1.05) at months 1, 3, 6, and 12, 
respectively, and significantly from 0.56 at baseline to 0.33 
at month 12 (P0.001). 
In the three-injection group, the mean baseline logMAR 
BCVA improved from 0.55±0.24 (range 0.30–1.05) to 
0.40±0.24 (range 0–1.00), 0.32±0.22 (range -0.07–0.82), 
0.30±0.22 (range 0–0.70) and 0.26±0.25 (range -0.18–0.70) 
at months 1, 3, 6, and 12, respectively, and significantly 
from 0.55 at baseline to 0.26 at month 12 (P0.001). The 
mean logMAR BCVA did not differ significantly at month 
12 between the two groups (P=0.389). 
The BCVA improved by 0.3 logMAR units or more at 
month 12 in nine (36%) eyes, remained stable in 14 (56%) 
eyes, and worsened by 0.3 logMAR units or more in two (8%) 
eyes in the single-injection group, and improved by 0.3 log-
MAR units or more at month 12 in 16 (59%) eyes, remained 
stable in ten (37%) eyes, and worsened by 0.3 logMAR units 
or more in one (4%) eye in the three-injection group. There 
was no between-group difference in the percentage of eyes 
with improved BCVA (P=0.093) or in the percentage of eyes 
with worsened logMAR BCVA (P=0.603). 
CFT
The mean CFT is shown in Figure 2. In the single-injection 
group, the mean ± standard deviation CFT decreased from 
598±186 µm at baseline to 347±133, 476±139, 384±141, 
and 348±134 µm at months 1, 3, 6, and 12, respectively, 
and decreased significantly (P0.001) from 598±186 µm at 
baseline to 348±134 µm at month 12. In the three-injection 
group, the mean CFT decreased significantly (P0.001) 
from 514±172 µm at baseline to 277±57, 256±65, 322±114, 
and 293±102 µm at months 1, 3, 6, and 12, respectively. The 
mean CFT at month 12 did not differ significantly between 
the two groups (P=0.101). 
number of additional injections
During the PRN period, additional injections were required in 
19 (76%) of 25 eyes in the single-injection group (one injec-
tion in eleven eyes, two injections in seven eyes, and three 
injections in one eye) and 16 (59%) of 27 eyes in the three-
injection group (one injection in four eyes, two injections in 
seven eyes, three injections in three eyes, four injections in 
one eye, and five injections in one eye). The mean number 
of additional injections was 1.1±0.8 in the single-injection 
Table 1 Baseline patient characteristics in the two treatment 
groups
Characteristic Three IVB 
group (n=27)
Single IVB 
group (n=25)
no patients 27 25
Female/male (eyes) 12/15 16/9
age (years, mean ± sD) 68.0±10.7 69.32±7.8
BCVa (logMar, mean ± sD) 0.55±0.24 0.56±0.22
CFT (µm, mean ± sD) 514±172 598±186
Abbreviations: iVB, intravitreal bevacizumab; BCVa, best-corrected visual acuity; 
CFT, central foveal thickness; logMar, logarithm of the minimum angle of resolution; 
sD, standard deviation.
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Figure 1 The change in the mean logarithm of the minimum angle of resolution 
best-corrected visual acuity (logMar BCVa) from baseline to month 12. 
Notes: in the one-injection group (solid circles), the mean logMar BCVa improved 
slightly from 0.56 at baseline to 0.47 at month 1 (P=0.04) and improved significantly 
to 0.33 at month 12 (P0.001). in the three-injection group (open circles), the mean 
logMar BCVa improved further to 0.40 at month 1 (P0.001) and improved significantly 
from 0.55 at baseline to 0.26 at month 12 (P0.001). There was no significant between-
group difference in the mean logMar BCVa at month 12 (P=0.389).
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Figure 2 The mean change in central foveal thickness (CFT) from baseline to month 12. 
Notes: The mean CFT decreased significantly from 598±186 µm at baseline to 
348±134 µm at month 12 in the one-injection group (solid circles; P0.001) and 
from 514±172 µm at baseline to 293±102 µm at month 12 in the three-injection 
group (open circles; P0.001). There was no significant between-group difference 
in the mean CFT at month 12 (P=0.101).
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group and 1.3±1.4 in the three-injection group. The number 
of additional injections did not differ significantly (P=0.507) 
between the two groups.
During the study period, the mean total number of 
injections was significantly smaller in the single-injection 
group than in the three-injection group (2.1±0.8 vs 4.3±1.4; 
P0.001).
Complications
No serious complications related to the IVB injections devel-
oped in either group.
Discussion
Previous studies have reported the efficacy of IVB for ME 
due to BRVO. However, few studies have reported the 
long-term efficacy of three monthly IVB injections and to 
our best knowledge, no studies have reported the results 
of treatment with single IVB injections and three monthly 
IVB injections in two prospective, consecutive groups of 
patients with ME following BRVO and compared the 1 year 
efficacy and safety results between these groups. A total of 
52 patients were enrolled in the study, ie, 25 consecutive 
eyes of 25 patients initially treated with one IVB injection 
followed by PRN treatment and 27 consecutive eyes of 
27 patients initially treated with three monthly IVB injections 
followed by PRN treatment. 
The mean logMAR BCVA improved significantly from 
0.56 at baseline to 0.33 at month 12 in the single injec-
tion group (P0.001) and from 0.55 at baseline to 0.26 
at month 12 in the three-injection group (P0.001). The 
current results were similar to those of previous studies 
(Table 2).12–15 Comparing the results among different stud-
ies is difficult because of the variations in inclusion criteria 
and different retreatment criteria. In the current study, 
1 year efficacy and safety results were compared between 
two groups of patients with ME after BRVO (a single IVB 
injection group and three monthly IVB injection group). 
The groups were comparable because we prospectively used 
the same inclusion criteria, the same retreatment criteria, and 
the same follow-up schedule except for the loading phase. 
Patients in the two groups were not randomized. However, 
we believe that the likelihood of sample selection bias was 
small because consecutive patients in the single-injection 
group were enrolled from August 2007 to March 2009, 
and consecutive patients in the three-injection group were 
enrolled from December 2009 to November 2010. After 
comparing the results, there was no significant (P=0.389) 
difference between the two groups regarding improvement 
in the logMAR BCVA.
Consistent with previous findings (Table 2),12–15 we found 
that the mean CFT decreased significantly from 598 µm 
at baseline to 348 µm at month 12 in the single-injection 
group (P0.001) and from 514 µm at baseline to 293 µm 
at month 12 in the three-injection group (P0.001). There 
was no significant (P=0.101) between-group difference in 
CFT improvement. 
Krohne et al reported that drug elimination from the 
aqueous humor closely parallels that from the vitreous and 
concluded that the aqueous half-life of 1.5 mg of intravitre-
ally injected bevacizumab in humans is 9.82 days.16 Miyake 
et al reported that the half-life of 1.25 mg of intravitreally 
injected bevacizumab in macaque eyes is 2.8 days in the aque-
ous humor.17 The half-life of bevacizumab is therefore short 
and retreatment is often required.16–18 In the current study, 
the average number of additional injections was 1.1 in the 
single-injection group, and re-injections were performed in 
19 (76%) eyes during the PRN period. In the three-injection 
group, the average number of additional injections was 1.3, 
and re-injections were performed in 16 (59%) eyes during 
the PRN period. Comparison of results of IVB injection at 
12 months between previous studies and the current study 
is shown in Table 2.
It is difficult to compare the mean number of additional 
injections among different studies because of inter-study 
Table 2 Comparison of results of intravitreal injection of bevacizumab at 12 months between previous studies and the current study
Study Current study  
single injection
Jaissle et al12 Kondo et al13 Current study three 
monthly  injections
Demir et al15
eyes 25 23 50 27 33
injections single single single Three monthly Three monthly
Baseline BCVa 0.56 0.50 0.53 0.55 0.66
BCVa at 12 months 0.33 0.20 0.26 0.26 0.22
Baseline CFT 598 395 523 514 494
CFT at 12 months 348 255 305 293 262
additional injections 1.1 2.4 1.0 1.3 2.3
Abbreviations: BCVa, best-corrected visual acuity; CFT, central foveal thickness.
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variation in inclusion criteria and retreatment criteria. In the 
current study, the mean number of additional injections was 
compared between the single-injection group and the three-
injection group because the same inclusion and retreatment 
criteria were used prospectively, and no significant between-
group difference in the number of additional injections was 
shown (P=0.507).
The mean total number of injections was smaller in the 
single-injection group than the three-injection group (2.1±0.8 
vs 4.3±1.4, respectively) because the mean number of addi-
tional injections was similar between the two groups. No 
serious complications developed in either group. Therefore, 
the single injection protocol was safer and less invasive than 
the three-injection one.
The mean CFT in the single-injection group increased 
at months 2 and 3 and retreatment guidelines prohibited 
additional injections. There was no significant difference 
in the logMAR BCVA between the two groups at months 2 
and 3 (P=0.403 and P=0.244, respectively). Increases in the 
CFT in the short term may not have an immediate effect on 
BCVA, whereas increases in the CFT in the long term may 
result in worsening of the BCVA.19
The absence of a significant between-group difference 
in the mean CFT and the logMAR BCVA at month 12 in 
patients with ME after BRVO indicated that one IVB injec-
tion followed by PRN treatment had similar effectiveness to 
three monthly IVB injections followed by PRN treatment in 
improving BCVA and CFT. Furthermore, the total number 
of injections was smaller in the single-injection group than 
in the three-injection group. 
No complications occurred in our two study groups, but 
severe side effects occurred in other studies. Minimizing the 
total number of injections reduces the risk of complications 
associated with IVB. 
Although circulating VEGF protects the integrity and pat-
ency of vessels, prolonged anti-VEGF treatment can increase 
the risk of thromboembolic events,20–22 and  reduced number 
of injections can lower the risk of serious adverse events. 
Notably, one limitation of our study was the relatively 
small number of patients with available imaging, pos-
sibly preventing our analysis from reaching statistical 
significance.
We showed that similar visual outcomes for ME second-
ary to BRVO may be achieved with fewer injections when 
one IVB injection is followed by PRN treatment rather than 
when three IVB injections are followed by PRN treatment; 
however, a prospective, double-masked, randomized study 
with a large number of patients is warranted.
Disclosure 
Supported in part by a grant from the Ministry of Education, 
Culture, Sports, Science and Technology of Japan (#24592668). 
The authors have no conflicts of interest to disclose.
References
 1. Cakir M, Dogan M, Bayraktar Z, et al. Efficacy of intravitreal triamci-
nolone for the treatment of macular edema secondary to branch retinal 
vein occlusion in eyes with or without grid laser photocoagulation. 
Retina. 2008;28(3):465–472.
 2. Rehak J, Rehak M. Branch retinal vein occlusion: Pathogen-
esis, visual prognosis, and treatment modalities. Curr Eye Res. 
2008;33(2):111–131.
 3. No authors listed. Argon laser photocoagulation for macular edema in 
branch vein occlusion. The branch vein occlusion study group. Am J 
Ophthalmol. 1984;98(3):271–282.
 4. Battaglia Parodi M, Saviano S, Ravalico G. Grid laser treatment in 
macular branch retinal vein occlusion. Graefes Arch Clin Exp Oph-
thalmol. 1999;237(12):1024–1027.
 5. Battaglia Parodi M, Saviano S, Bergamini L, Ravalico G. Grid laser 
treatment of macular edema in macular branch retinal vein occlusion. 
Doc Ophthalmol. 1999;97(3–4):427–431.
 6. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection 
for treatment of macular edema secondary to branch retinal vein occlu-
sion. Retina. 2005;25(7):851–855.
 7. Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ohji M. 
Prospective comparisons of intravitreal injections of triamcinolone 
acetonide and bevacizumab for macular oedema due to branch retinal 
vein occlusion. Acta Ophthalmol. 2013;91(4):318–324. 
 8. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intra-
vitreal bevacizumab (avastin) in the treatment of macular edema second-
ary to branch retinal vein occlusion. Retina. 2007;27(4):419–425.
 9. Gunduz K, Bakri SJ. Intravitreal bevacizumab for macular 
oedema secondary to branch retinal vein occlusion. Eye (Lond). 
2008;22(9):1168–1171.
 10. Moradian S, Faghihi H, Sadeghi B, et al. Intravitreal bevacizumab vs 
Sham treatment in acute branch retinal vein occlusion with macular 
edema: Results at 3 months (report 1). Graefes Arch Clin Exp Oph-
thalmol. 2011;249(2):193–200.
 11. Yunoki T, Miyakoshi A, Nakamura T, Fujita K, Fuchizawa C, Hayashi A. 
Treatment of macular edema due to branch retinal vein occlusion 
with single or multiple intravitreal injections of bevacizumab. Jpn J 
Ophthalmol. 2012;56(2):159–164.
 12. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, 
Szurman P. One-year results after intravitreal bevacizumab therapy 
for macular edema secondary to branch retinal vein occlusion. Graefes 
Arch Clin Exp Ophthalmol. 2009;247(1):27–33.
 13. Kondo M, Kondo N, Ito Y, et al. Intravitreal injection of bevacizumab 
for macular edema secondary to branch retinal vein occlusion: Results 
after 12 months and multiple regression analysis. Retina. 2009; 
29(9):1242–1248.
 14. Byun YJ, Roh MI, Lee SC, Koh HJ. Intravitreal triamcinolone 
acetonide versus bevacizumab therapy for macular edema associated 
with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 
2010;248(7):963–971.
 15. Demir M, Oba E, Gulkilik G, Odabasi M, Ozdal E. Intravitreal 
bevacizumab for macular edema due to branch retinal vein occlusion: 
12-month results. Clin Ophthalmol. 2011;5:745–749.
 16. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics 
of bevacizumab after a single intravitreal injection in humans. Am J 
Ophthalmol. 2008;146(4):508–512.
 17. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevaci-
zumab and its effect on vascular endothelial growth factor after intra-
vitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol 
Vis Sci. 2010;51(3):1606–1608.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
20
2.
19
.1
44
.3
9 
on
 0
6-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
180
ito et al
 18. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharma-
cokinetics of intravitreal bevacizumab (avastin). Ophthalmology. 
2007;114(5):855–859.
 19. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (vegf trap-eye) 
in wet age-related macular degeneration. Ophthalmology. 2012;119(2): 
2537–2548.
 20. Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboem-
bolic adverse events in patients treated with intravitreal anti-VEGF 
drugs for neovascular age-related macular degeneration. Expert Opin 
Biol Ther. 2012;12(10):1299–1313.
 21. Semeraro F, Morescalchi F, Duse S, Gambicorti E, Romano MR, 
Costagliola C. Systemic thromboembolic adverse events in patients 
treated with intravitreal anti-VEGF drugs for neovascular age-related 
macular degeneration: an overview. Expert Opin Drug Saf. 2014; 
13(6):785–802.
 22. Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA. 
Efficacy and adverse events of aflibercept, ranibizumab and 
bevacizumab in age-related macular degeneration: a trade-off analysis. 
Br J Ophthalmol. Epub 2014 Jun 11. 
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
20
2.
19
.1
44
.3
9 
on
 0
6-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
